title: ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÑÐ½Ð½Ð¾Ð¹ Ð´Ð¾Ð·Ñ Ð² Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ð¿ÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ 225Ac- DOTA-TATE
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Determination of the absorbed dose in pathological foci and critical organs in patients with radionuclide therapy 225-AC DOTA-TATE
Creators: name: ÐÐ°ÑÑÐ½Ð¾Ð²Ð°, ÐÐºÐ°ÑÐµÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
ÑÐµÑÐ°Ð½Ð¾ÑÑÐ¸ÐºÐ°
Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ð¹ Ð¾ÑÐ°Ð³
ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð¾ÑÐ³Ð°Ð½
Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ
ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð°ÑÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð»ÐµÐºÐ°ÑÑÑÐ²ÐµÐ½Ð½ÑÐ¹ Ð¿ÑÐµÐ¿Ð°ÑÐ°Ñ
radionuclide therapy
theranostics
pathological focus
dense organ
absorbing doses
radiopharmaceutical drug

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¿ÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ 225ÐÑ-ÐÐÐ¢Ð-Ð¢ÐÐ¢Ð Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ð¸ ÐÐ­Ð¢/ÐÐ¢ ÑÐºÐ°Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ð¹ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ 68Ga-ÐÐÐ¢Ð-Ð¢ÐÐ¢Ð. ÐÐ°Ð´Ð°ÑÐ¸, ÐºÐ¾ÑÐ¾ÑÑÐµ ÑÐµÑÐ°Ð»Ð¸ÑÑ Ð² ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ: 1. ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ 68Ga-ÐÐÐ¢Ð-Ð¢ÐÐ¢Ð Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ð¸ ÐÐ­Ð¢/ÐÐ¢ ÑÐºÐ°Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ð¹. 2. ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¸Ð½ÑÐµÐ³ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÑ Ð¿Ð¾ Ð²ÑÐµÐ¼ÐµÐ½Ð¸ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐµÐ¹ 225ÐÑ- ÐÐÐ¢Ð-Ð¢ÐÐ¢Ð Ð² Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÑÐ°Ð´Ð¸Ð¾ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½ÑÑ Ð¾ÑÐ³Ð°Ð½Ð°Ñ. 3. ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¿ÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ 225ÐÑ-ÐÐÐ¢Ð- Ð¢ÐÐ¢Ð Ñ ÑÑÐµÑÐ¾Ð¼ Ð´Ð¾Ð· Ð¾Ñ Ð´Ð¾ÑÐµÑÐ½Ð¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð². Ð Ð°Ð±Ð¾ÑÐ° Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð° Ð½Ð° Ð±Ð°Ð·Ðµ Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ ÑÐ°Ð´Ð¸Ð°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ Ð³Ð¸Ð³Ð¸ÐµÐ½Ñ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½ÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð°ÑÐ¸Ð¹ Ð¤ÐÐ£Ð ÐÐÐÐ Ð Ð¸Ð¼. Ð.Ð. Ð Ð°Ð¼Ð·Ð°ÐµÐ²Ð° Ð¸ Ð½Ð° Ð±Ð°Ð·Ðµ Ð¾ÑÐ´ÐµÐ»ÐµÐ½Ð¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð¸Ð·Ð¾ÑÐ¾Ð¿Ð½Ð¾Ð¹ Ð¿Ð¾Ð·Ð¸ÑÑÐ¾Ð½Ð½Ð¾-ÑÐ¼Ð¸ÑÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ¾Ð¼Ð¾Ð³ÑÐ°ÑÐ¸Ð¸ Ð¤ÐÐÐ£ Â«Ð ÐÐ¦Ð Ð¥Ð¢ Ð¸Ð¼. Ð°Ðº. Ð.Ð. ÐÑÐ°Ð½Ð¾Ð²Ð°Â». Ð Ð°ÑÑÐµÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸Ð»ÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ð½Ð¾Ð³Ð¾ Ð¾Ð±ÐµÑÐ¿ÐµÑÐµÐ½Ð¸Ñ âIDAC-DOSE 2.1â. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð¸ Ð¾ÑÐµÐ½ÐµÐ½Ñ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð¿ÑÐ¸ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ 225ÐÑ-ÐÐÐ¢Ð-Ð¢ÐÐ¢Ð Ñ ÑÑÐµÑÐ¾Ð¼ Ð´Ð¾Ð· Ð¾Ñ Ð´Ð¾ÑÐµÑÐ½Ð¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð².
description: The given work is devoted to the determination of absorbed doses in pathological foci and critical organs during radionuclide therapy with 225Ac-DOTA-TATE based on PET/CT scans using 68Ga-DOTA-TATE. Tasks that were solved during the work: 1. Determination of the accumulated activity of 68Ga-DOTA-TATE based on PET/CT scans. 2. Determination of time-integrated 225Ac-DOTA-TATE activities in pathological foci and radiosensitive organs. 3. Determination of absorbed doses in pathological foci and critical organs during radionuclide therapy with 225Ac-DOTA-TATE, considering doses from daughter radionuclides. The work was carried out based on the laboratory of radiation hygiene of medical organizations of the FBUN NIIRG named after V.I. P.V. Ramzaev and on the basis of the department of radioisotope positron emission tomography of the Federal State Budgetary Institution "RRTCST named after Academician A. M. Granov. Calculations of absorbed doses in pathological foci and critical organs were carried out using the software "IDAC-DOSE 2.1" As a result, absorbed doses were estimated during radionuclide therapy with 225Ac-DOTA-TATE, considering doses from daughter radionuclides.